Avita Medical (ASX: AVH) received US Food and Drug Administration approval for its premarket approval supplement for the Recell Go mini, a disposable cartridge designed to treat smaller wounds up to 480 square centimeters, according to a Tuesday filing with the Australian bourse.
This extends the company's Recell Go platform, which previously handled larger wounds up to 1,920 square centimeters, the filing said.
The regenerative medicine company plans to roll out the product in the first quarter of 2025, targeting broader access to smaller wound care.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。